Cart
0
Get 20% Free Customization In This Report
By this report from - $3759

Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules (Genetic Biomarkers, Protein Biomarkers, Glycoprotein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer), Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

LI 161443
Pages: 172
Dec 2016 | 1896 Views
face gplus_n
Author's : Mohd. Adnan Malik
Tables: 62
Charts: 75
twit_n pr_n

Cancer Biomarkers Market Overview:

Global Cancer Biomarkers Market size is $15,737 million by 2022, registering a CAGR of 13.3% from 2016 to 2022. Cancer biomarkers are molecules released during the presence of a tumor or a particular indication in the body to the presence of cancer. These are either substance, molecule or a physical event that indicate the existence of cancerous cells in the body. These molecules are generally found in tissues, urine, serum, blood, and other body fluids that indicate any abnormal process or a disease.

Cancer biomarkers are traceable substances that can be used as an indicator of biological state of tumor and thus it can be used to analyze diagnostic and prognostic stages of cancer. The prevention of cancer by diagnosing and analyzing various cancer biomarkers using different diagnostic techniques is a profound approach for obtaining rapid results for treatment. These biomarkers are used as risk indicators for various cancer types such as lung cancer, breast cancer, and prostate cancer among others. Some of the key biomarkers that are widely used include CEA, SCC, NSE Cyfra 21-1 and TPA (lung cancer), PSA (prostate cancer) and CA15-3, EGF R, BRCA 1/2 and Cytokeratin 14 (breast cancer).
 
Global Cancer Biomarkers Market Segmentation
 
Global Cancer Biomarkers Market Segmentation

Global Cancer biomarkers market is broadly segmented based on profiling technology, biomolecules, cancer type, application, and geography. By profiling technology, the cancer biomarker industry is segmented into omic technologies, imaging technologies, immunoassays, and cytogenetics based tests. Omic technologies segment occupies the largest cancer biomarker market size. Based on biomolecules, the cancer biomarker industry is segmented into genetic biomarkers, protein biomarkers, and glycoprotein biomarkers. Genetic biomarkers occupies the largest cancer biomarker market share. The various cancer type include breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others; among which breast cancer accounts for the largest cancer biomarker market size. Based on application, the market can be segmented into diagnostics, drug discovery and development, prognostics, risk assessment, and others. Prognostics segments occupies the largest cancer biomarker market share.Geographically, the global cancer biomarkers market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is the leading revenue generating region, due to high incidence rate of cancer, growth in awareness towards cancer and higher cancer biomarker testing, whereas Asia-Pacific is growing at the fastest CAGR due to increasing disposable incomes, increasing awareness, and rising affordability for advanced cancer treatments.
 
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and personal interactions. In addition, our corporate relations with various companies allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
  • Validate and improve the data quality and strengthen research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecasts
 
Primary Respondents: % Split
 
Primary Respondents: % Split

Our primary research interview and discussion panels comprise most experienced industry members. These participants include; however, not limited to:
  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts
  • Key opinion leaders (KOLs)

Top Impacting Factors

The need for cancer biomarkers is expected to increase globally during the forecast period majorly due to the alarming prevalence of cancer cases. However, reluctance in adoption of new technologies, high cost of biomarker techniques, and low detection rate are anticipated to restrain the market growth. Moreover, increasing positive effects of the drivers is likely to reveal new market opportunities for the key players. The details of the key factors are explained below:
 
Top Impacting Factors: Global Cancer Biomarkers Market, 2015-2022
 
Top Impacting Factors: Global Cancer Biomarkers Market, 2015-2022

Drivers

Rising Incidence and Prevalence of Various Cancer Types

The global population has witnessed an alarming surge in cancer, with about 14 million new cancer cases reported each year. The following table depicts the worldwide incidences and the five-year prevalence of cancer in 2012, estimated by World Health Organization (WHO). According to WHO, it is anticipated to further increase over the next two decades by 70% with 22 million new cancer cases. Cancer is highly prevalent in lower and middle income countries as they lack suitable healthcare infrastructure to effectively combat the condition. In the year 2012, WHO estimated that 57% of new cancer cases and 48% of five year prevalent cases occurred in developing or under-developed regions. In addition, the cancer cases were 25% higher in men than in women.

Major companies have adopted collaboration and partnership as their key development strategy. The key players of the cancer biomarkers industry include F.Hoffmann-La Roche Ltd., Abbott Laboratories, GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Inc., Qiagen N.V. and Genomic Health, Inc. The other players in the value chain include: bioMérieux, Astellas Pharma Inc., Myriad Genetics, Epigenomics and Radient Pharmaceuticals.

*Profiles of these companies are not included. However, the same will be included as per the request

Key Benefits for Stakeholders:
 
  • The projections in the report are made by analyzing the current cancer biomarkers market trends and future market potential in terms of value. The analysis helps in understanding the strategies adopted by various companies for the growth of the global cancer biomarkers market.
  • Comprehensive analysis of the factors that drive and restrict the growth of the global cancer biomarkers market is provided.
  • The market conditions of the global cancer biomarkers market across all regions are comprehensively analyzed.
  • Porter's five forces model gives an in-depth analysis of bargaining power of buyers and suppliers, threats of new entrants and substitutes and competition amongst the key market players.
  • Prime focus of the report is to reveal opportunities-analysis within this Cancer Biomarkers market with respect to cancer biomarkers industry.

Cancer Biomarkers Market Key Segments:

By Profiling Technology

  • Omic Technologies
  • Imaging Technologies
  • Immunoassays
  • Cytogenetics Based Tests

By Biomolecules

  • Genetic Biomarkers
  • Protein Biomarkers
  • Glycoprotein Biomarkers

By Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Other Cancers

By Application

  • Diagnostics
  • Drug Discovery and Development
  • Prognostics
  • Risk Assessment
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO perspective

Chapter: 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Biomarker diagnosis vs. conventional diagnosis
3.3 Key findings

3.3.1 Drivers

3.3.1.1 Rise in incidence and prevalence of various cancer types
3.3.1.2 Growth in importance of biological and targeted drug therapies
3.3.1.3 Expiration of key patents and biosimilars impact
3.3.1.4 Increase in acquisitions and collaborations
3.3.1.5 Technological advancements
3.3.1.6 Accuracy and reliability
3.3.1.7 Rise in investment from government, public, and private sectors
3.3.1.8 Increase in clinical trials
3.3.1.9 Growth in popularity of personalized medicine and companion diagnostics

3.3.2 Restraints

3.3.2.1 High cost of drug development and threat of failure
3.3.2.2 Unregulated government regulation and reimbursement policies
3.3.2.3 Adverse effects of cancer drug therapy

3.3.3 Opportunities

3.3.3.1 Advancement of cancer drugs research
3.3.3.2 Increased focus towards advanced treatment protocols
3.3.3.3 Significant unmet need in cancer diagnosis
3.3.3.4 Increased awareness to reduce healthcare costs
3.3.3.5 Opportunities in emerging economies

3.3.4 Top investment pockets
3.3.5 Top winning strategies

3.4 Porters five forces analysis

3.4.1 High bargaining power of suppliers
3.4.2 Low bargaining power of buyers
3.4.3 High threat from substitutes
3.4.4 Low threat of new entrants
3.4.5 High intensity of competitive rivalry

3.5 Top player positioning, 2015
3.6 Patent analysis

3.6.1 U.S. patent analysis by market participant
3.6.2 Europe patent analysis by market participant
3.6.3 China patent analysis by market participant
3.6.4 Canada patent analysis by market participant
3.6.5 Japan patent analysis by market participant
3.6.6 Other countries patent analysis by market participant

3.7 Clinical trials

Chapter: 4 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022

4.1 Overview

4.1.1 Market size and forecast

4.1 Omic technologies

4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast
4.1.4 Genomics

4.1.4.1 Market size and forecast
4.1.4.2 Next-generation sequencing (NGS)
4.1.4.3 Microarray
4.1.4.4 Polymerase chain reaction (PCR)

4.1.5 Proteomics

4.1.5.1 Market size and forecast
4.1.5.2 Mass spectrometry
4.1.5.3D gel electrophoresis
4.1.5.4 Protein microarray technology
4.1.5.5 Antibody array technology
4.1.5.6 Peptide array technology

4.1.6 Other omic technologies

4.1.6.1 Market size and forecast
4.1.6.2 Metabolomics
4.1.6.3 Glycomics

4.2 Imaging technologies

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 Magnetic resonance imaging
4.2.5 Positron emission tomography
4.2.6 Computed tomography
4.2.7 Mammography
4.2.8 Ultrasound

4.3 Immunoassays

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.3.4 Immunohistochemistry tests
4.3.5 Enzyme-linked immunosorbent assay
4.3.6 Flow cytometry

4.4 Cytogenetics-based tests

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.4.4 In situ hybridization
4.4.5 Others (karyotyping, amplichip, and in vitro diagnostic multivariate index assays [IVDMIA])

Chapter: 5 GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE (2014-2022)

5.1 Overview

5.1.1 Market size and forecast

5.2 Genetic biomarkers

5.2.1 Market size and forecast

5.3 Protein biomarkers

5.3.1 Market size and forecast

5.4 Glyco-biomarkers

5.4.1 Market size and forecast

Chapter: 6 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022

6.1 Overview

6.1.1 Market size and forecast

6.2 Lung cancer

6.2.1 Market size and forecast

6.3 Breast cancer

6.3.1 Market size and forecast

6.4 Colorectal cancer

6.4.1 Market size and forecast

6.5 Prostate cancer

6.5.1 Market size and forecast

6.1 Stomach cancer

6.1.1 Market size and forecast

6.2 Others

6.2.1 Market size and forecast

Chapter: 7 CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022

7.1 Overview

7.1.1 Market size and forecast

7.2 Diagnostics

7.2.1 Market size and forecast

7.3 Drug discovery and development

7.3.1 Market size and forecast

7.4 Prognostics

7.4.1 Market size and forecast

7.5 Risk assessment

7.5.1 Market size and forecast

7.6 Others (personalized medicine, surrogate endpoints, recurrence, and therapeutics)

7.6.1 Market size and forecast

Chapter: 8 CANCER BIOMARKERS MARKET BY GEOGRAPHY, 2014-2022

8.1 Overview

8.1.1 Market size and forecast

8.2 North America

8.2.1 Key market trends
8.2.2 Growth factors and opportunities
8.2.3 Market size and forecast

8.2.3.1 U.S.: market size and forecast
8.2.3.2 Canada: market size and forecast
8.2.3.3 Mexico: market size and forecast

8.3 Europe

8.3.1 Key market trends
8.3.2 Growth factors and opportunities
8.3.3 Market size and forecast

8.3.3.1 Germany: market size and forecast
8.3.3.2 UK: market size and forecast
8.3.3.3 France: market size and forecast
8.3.3.4 Italy: market size and forecast
8.3.3.5 Russia: market size and forecast
8.3.3.6 Rest of Europe: market size and forecast

8.4 Asia-Pacific

8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast

8.4.3.1 Japan: market size and forecast
8.4.3.2 China: market size and forecast
8.4.3.3 India: market size and forecast
8.4.3.4 Australia: market size and forecast
8.4.3.5 Rest of Asia-Pacific: market size and forecast

8.5 LAMEA (Latin America, Middle East, and Africa)

8.5.1 Key market trends
8.5.2 Key growth factors and opportunities

8.5.2.1 Brazil: market size and forecast
8.5.2.2 Saudi Arabia: market size and forecast
8.5.2.3 UAE: market size and forecast
8.5.2.4 Rest of LAMEA: market size and forecast

Chapter: 9 COMPANY PROFILES

9.1 F. Hoffmann-La Roche Ltd.

9.1.1 Company overview
9.1.2 Business performance
9.1.3 Key strategies and developments

9.2 Abbott Laboratories

9.2.1 Company overview
9.2.2 Company Snapshot
9.2.3 Operating business segments
9.2.4 Business performance
9.2.5 Key strategies & developments

9.3 GlaxoSmithKline plc

9.3.1 Company overview
9.3.2 Operating business segments
9.3.3 Business performance
9.3.4 Key strategies and developments

9.4 Novartis AG

9.4.1 Company overview
9.4.2 Operating business segments
9.4.3 Business performance
9.4.4 Key strategies and developments

9.5 Merck & Co., Inc.

9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Business performance
9.5.5 Key strategies and developments

9.6 Bristol-Myers Squibb

9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Business performance
9.6.4 Key strategies and developments

9.7 Eli Lilly and Company

9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Business performance
9.7.5 Key strategies and developments

9.8 Pfizer, Inc.

9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Business performance
9.8.5 Key strategies and developments

9.9 Qiagen N.V.

9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Key strategy move and development

9.10 Genomic Health, Inc.

9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Business performance
9.10.4 Key strategies and developments

List of Figures

FIG. 1 CANCER BIOMARKERS MARKET: SEGMENTATION
FIG. 2 TOP IMPACTING FACTORS: CANCER BIOMARKERS MARKET, 2015-2022
FIG. 3 PERCENTAGE (%) OF NEW CANCERS CASES DIAGNOSED IN 2012
FIG. 4 TOP INVESTMENT POCKETS: CANCER BIOMARKERS, 2015-2022
FIG. 5 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION
FIG. 6 TOP WINNING STRATEGIES: NATURE & TYPE
FIG. 7 TYPES OF STRATEGIES DISTRIBUTION
FIG. 8 DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIG. 9 DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIG. 10 PORTERS FIVE FORCES ANALYSIS
FIG. 11 TOP PLAYER POSITIONING, 2015
FIG. 12 PATENTS REGISTERED/APPROVED IN THE WORLD, 2013-2016
FIG. 13 U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 14 EUROPE: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 15 CHINA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 16 CANADA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 17 JAPAN: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 18 OTHERS: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 19 U.S.: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 20 CANADA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 21 MEXICO: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 22 GERMANY: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 23 U.K.: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 24 FRANCE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 25 ITALY: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 26 RUSSIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 27 REST OF EUROPE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 28 JAPAN: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 29 CHINA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 30 INDIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 31 AUSTRALIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 32 REST OF ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 33 BRAZIL: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 34 SAUDI ARABIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 35 UAE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 36 REST OF LAMEA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 37 ROCHE: NET SALES, 2013-2015 ($MILLION)
FIG. 38 ROCHE: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 39 ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 40 ROCHE: STRATEGY SHARE, 2014-2016 (%)
FIG. 41 ABBOTT: NET SALES, 2013-2015 ($MILLION)
FIG. 42 ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
FIG. 43 ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
FIG. 44 ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 45 ABBOTT: STRATEGY SHARE, 2014-2016 (%)
FIG. 46 GSK: NET SALES, 2013-2015 ($MILLION)
FIG. 47 GSK: REVENUE, BY SEGMENT, 2015 (%)
FIG. 48 GSK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 49 GSK: STRATEGY SHARE, 2014-2016 (%)
FIG. 50 NOVARTIS: REVENUE, 2013-2015 ($MILLION)
FIG. 51 NOVARTIS: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 52 NOVARTIS: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 53 NOVARTIS: STRATEGY SHARE, 2014-2016 (%)
FIG. 54 MERCK: NET SALES, 2013-2015 ($MILLION)
FIG. 55 MERCK: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 56 MERCK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 57 MERCK: STRATEGY SHARE, 2014-2016 (%)
FIG. 58 BRISTOL-MYERS SQUIBB: NET SALES, 2013-2015 ($MILLION)
FIG. 59 BRISTOL-MYERS SQUIBB, REVENUE, BY GEOGRAPHY, 2015(%)
FIG. 60 BRISTOL-MYERS SQUIBB: STRATEGY SHARE, 2014-2016 (%)
FIG. 61 ELI LILLY: NET SALES, 2013-2015, ($MILLION)
FIG. 62 ELI LILLY: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 63 ELI LILLY: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 64 ELI LILLY: STRATEGY SHARE, 2014-2016 (%)
FIG. 65 PFIZER, INC.: NET SALES, 2013-2015, ($MILLION)
FIG. 66 PFIZER, INC.: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 67 PFIZER, INC.: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 68 PFIZER, INC.: STRATEGY SHARE, 2014-2016 (%)
FIG. 69 QIAGEN: NET SALES, 2013-2015, ($MILLION)
FIG. 70 QIAGEN: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 71 QIAGEN: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 72 QIAGEN: STRATEGY SHARE, 2014-2016 (%)
FIG. 73 GENOMIC HEALTH: NET SALES, 2013-2015 ($MILLION)
FIG. 74 GENOMIC HEALTH: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 75 GENOMIC HEALTH: STRATEGY SHARE, 2014-2016 (%)

List of Tables

TABLE 1 CONVENTIONAL DIAGNOSTICS VS. DIAGNOSTIC BIOMARKER TECHNIQUES
TABLE 2 WORLDWIDE ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES (2012)
TABLE 3 REVENUE GENERATION OF BIOLOGICAL AND TARGETED DRUGS IN 2013 ($MILLION)
TABLE 4 KEY PRODUCTS WITH THEIR PATENT EXPIRY DATES
TABLE 5 COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF CANCER DRUGS
TABLE 6 PATENTS REGISTERED/APPROVED IN THE U.S., EUROPE, CANADA, CHINA, JAPAN, AND OTHERS, 2013 THROUGH 2016
TABLE 7 U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 8 EUROPE: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 9 CHINA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016
TABLE 10 CANADA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016
TABLE 11 JAPAN: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 12 OTHERS: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 13 CLINICAL TRIALS: CANCER BIOMARKERS
TABLE 14 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 15 WORLD OMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 16 WORLD OMICS TECHNOLOGY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17 GLOBAL GENOMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 1 GLOBAL PROTEOMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 2 GLOBAL OTHER OMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 3 GLOBAL IMAGING TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 4 GLOBAL IMAGING TECHNOLOGY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 5 GLOBAL IMMUNOASSAYS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 6 GLOBAL IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 7 GLOBAL CYTOGENETICS-BASED TESTS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 8 GLOBAL CYTOGENETICS-BASED TESTS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 9 GLOBAL CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 10 GLOBAL GENETIC BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 11 GLOBAL PROTEIN BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12 GLOBAL GLYCO-BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 14 GLOBAL CANCER BIOMARKERS FOR LUNG CANCER, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15 GLOBAL CANCER BIOMARKERS FOR BREAST CANCER, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 16 GLOBAL CANCER BIOMARKERS FOR COLORECTAL CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17 GLOBAL CANCER BIOMARKERS FOR PROSTATE CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 18 GLOBAL CANCER BIOMARKERS FOR STOMACH CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 19 GLOBAL CANCER BIOMARKERS FOR OTHER CANCERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 20 CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 21 DIAGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 22 DRUG DISCOVERY AND DEVELOPMENT MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 23 PROGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 24 RISK ASSESSMENT MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 25 OTHERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 26 CANCER BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 27 NORTH AMERICA CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 28 NORTH AMERICA CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 29 NORTH AMERICA CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 30 NORTH AMERICA CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 31 NORTH AMERICAN CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 32 EUROPEAN CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 33 EUROPEAN CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 34 EUROPEAN CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 35 EUROPEAN CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 36 EUROPEAN CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 37 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 38 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 39 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 40 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 41 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 42 LAMEA CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 43 LAMEA CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 44 LAMEA CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 45 LAMEA CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 46 LAMEA CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 47 ROCHE: COMPANY SNAPSHOT
TABLE 48 ABBOTT: COMPANY SNAPSHOT
TABLE 49 ABBOTT: OPERATING SEGMENTS
TABLE 50 GSK: COMPANY SNAPSHOT
TABLE 51 GSK: OPERATING SEGMENTS
TABLE 52 NOVARTIS: COMPANY SNAPSHOT
TABLE 53 NOVARTIS: OPERATING SEGMENTS
TABLE 54 MERCK: COMPANY SNAPSHOT
TABLE 55 MERCK: PRODUCT CATEGORIES
TABLE 56 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 57 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 58 ELI LILLY: OPERATING SEGMENTS
TABLE 59 PFIZER, INC.: COMPANY SNAPSHOT
TABLE 60 PFIZER, INC.: OPERATING SEGMENTS
TABLE 61 QIAGEN: COMPANY SNAPSHOT
TABLE 62 GENOMIC HEALTH: COMPANY SNAPSHOT

 
 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 

Get More Information About This Report

For any queries about purchasing this report, Please fill the form below:

Please input the above text in the input box or click refresh

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts